News | October 23, 2019

ARVINAS PRESENTS A PLATFORM UPDATE, INCLUDING INITIAL DATA FROM THE FIRST TWO CLINICAL TRIALS OF PROTAC® TARGETED PROTEIN DEGRADERS -Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally...

News | November 21, 2019

HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOON’S BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the...

News | November 18, 2019

Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection Topline results expected in Q1 2020 DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics...

News | November 5, 2019

New Patient Access Survey Shows Consumers Are Increasingly Self-Empowered in Their Care Decisions and Place a Growing Premium on Convenience Third Annual Survey from Kyruus Underscores the Need for Health Systems to Meet Patient Demand for Streamlined Access and...

News | November 7, 2019

Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer SAN DIEGO, Calif., November 7, 2019 – Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has appointed...

News | November 6, 2019

ARVINAS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the...